R. Oliveri

发表

How I treat patients with massive hemorrhage.

C. Wade, J. Holcomb, S. Ostrowski, 2014, Blood.

Evaluation in mammalian oocytes of gene transcripts linked to epigenetic reprogramming.

A. Byskov, R. Borup, C. Andersen, 2007, Reproduction.

Hemostatic resuscitation with plasma and platelets in trauma

S. Ostrowski, P. Johansson, R. Oliveri, 2012, Journal of emergencies, trauma, and shock.

The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products – A systematic review and meta-analysis

P. Johansson, R. Oliveri, Mathilde Fahrendorff, 2017, Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.

How I Treat How I treat patients with massive hemorrhage

C. Wade, J. Holcomb, S. Ostrowski, 2014 .

Mesenchymal stem cells improve locomotor recovery in traumatic spinal cord injury: Systematic review with meta-analyses of rat models

F. Biering-Sørensen, R. Oliveri, S. Bello, 2014, Neurobiology of Disease.

Regional differences in expression of specific markers for human embryonic stem cells.

N. Tommerup, K. Møllgård, A. Andersen, 2007, Reproductive biomedicine online.

Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies.

A. Bardow, L. Specht, C. Buchwald, 2014, Oral surgery, oral medicine, oral pathology and oral radiology.

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

P. Lugtenburg, M. Hutchings, S. Rule, 2019, Blood.

Cell-associated HIV DNA Measured Early During Infection has Prognostic Value Independent of Serum HIV RNA Measured Concomitantly

T. Benfield, C. Nielsen, J. Eugen-Olsen, 2002, Scandinavian journal of infectious diseases.

Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

M. Sormani, E. Radue, M. Freedman, 2021, The Lancet Neurology.

Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas

T. Salcedo, R. Oliveri, T. Ahmadi, 2022, Clinical pharmacology and therapeutics.

Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.

S. Kenwrick, M. Sehested, L. Jensen, 1998, Cancer research.

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

M. Sormani, E. Radue, M. Freedman, 2019, Trials.

Pooled human platelet lysate versus fetal bovine serum-investigating the proliferation rate, chromosome stability and angiogenic potential of human adipose tissue-derived stem cells intended for clinical use.

K. Drzewiecki, M. Kirchhoff, R. Oliveri, 2013, Cytotherapy.

Epigenetic dedifferentiation of somatic cells into pluripotency: cellular alchemy in the age of regenerative medicine?

Roberto S Oliveri, R. Oliveri, 2007, Regenerative medicine.

Enrichment of autologous fat grafts with ex-vivo expanded adipose tissue-derived stem cells for graft survival: a randomised placebo-controlled trial

J. Kastrup, K. Drzewiecki, M. Kirchhoff, 2013, The Lancet.

First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a randomized controlled trial

C. von Buchwald, A. Bardow, S. Jensen, 2017, Trials.

Importance of mesenchymal stem cells in autologous fat grafting: A systematic review of existing studies

K. Drzewiecki, R. Oliveri, J. Elberg, 2012, Journal of plastic surgery and hand surgery.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

P. Lugtenburg, M. Hutchings, A. Azaryan, 2021, The Lancet.

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

D. Cunningham, P. Lugtenburg, M. Hutchings, 2020 .

Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX).

C. von Buchwald, A. Bardow, S. Jensen, 2018, International journal of radiation oncology, biology, physics.

Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.

Juanita Lopez, P. Lugtenburg, M. Hutchings, 2020 .

Transcatheter arterial embolisation and chemoembolisation for hepatocellular carcinoma

C. Gluud, R. Oliveri, 2004 .

Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.

J. Wetterslev, C. Gluud, R. Oliveri, 2011, The Cochrane database of systematic reviews.

Hospital doctors' self-rated skills in and use of evidence-based medicine - a questionnaire survey.

Christian Gluud, Roberto S Oliveri, P. Wille-Jørgensen, 2004, Journal of evaluation in clinical practice.

PRECLINICAL EVALUATION OF EPCORITAMAB COMBINED WITH STANDARD OF CARE AGENTS FOR THE TREATMENT OF B‐CELL LYMPHOMAS

E. Szafer-Glusman, M. Jure-Kunkel, P. G. Castro, 2021, Hematological Oncology.

Immunoflourescence and mRNA analysis of human embryonic stem cells (hESCs) grown under feeder-free conditions.

Aashir Awan, S. Christensen, C. Andersen, 2010, Methods in molecular biology.

How I treat patients with massive hemorrhage.

C. Wade, J. Holcomb, S. Ostrowski, 2014, Blood.

First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a randomized controlled trial

C. von Buchwald, A. Bardow, S. Jensen, 2017, Trials.